Bionomics Limited

0.25
0.01 (3.31%)
At close: Dec 23, 2024, 9:00 PM

Company Description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States.

The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder.

It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Bionomics Limited has a licensing agreement with Merck & Co., Inc.

The company was incorporated in 1996 and is based in Eastwood, Australia.

Bionomics Limited
Bionomics Limited logo
Country AU
IPO Date Dec 16, 2021
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Dr. Spyridon Papapetropoulos M.D., Ph.D.

Contact Details

Address:
200 Greenhill Road
Eastwood, SA
AU
Website https://www.bionomics.com.au

Stock Details

Ticker Symbol BNOX
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001191070
CUSIP Number 09063M205
ISIN Number US09063M2052
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Spyridon Papapetropoulos M.D., Ph.D. Chief Executive Officer, President & Director
Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer
Adrian Hinton BEC, F.C.A. Financial Controller
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations
Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer
Elizabeth Doolin Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Dec 23, 2024 8-K Current Report
Dec 23, 2024 POS AM Filing
Dec 23, 2024 POS AM Filing
Dec 23, 2024 15-12G Filing
Dec 16, 2024 8-K Current Report
Dec 12, 2024 8-K Current Report
Nov 25, 2024 S-3/A [Amend] Filing
Nov 21, 2024 8-K Current Report
Nov 18, 2024 S-3 Filing
Nov 14, 2024 10-Q Quarterly Report